Benign familial infantile epilepsy (BFIE) is clinically characterized by clusters of brief partial seizures progressing to secondarily generalized seizures with onset at the age of 3-7 months and with favorable outcome. PRRT2 mutations are the most common cause of BFIE, and found in about 80% of BFIE families. In this study, we analyzed a large multiplex BFIE family by linkage and whole exome sequencing (WES) analyses. Genome-wide linkage analysis revealed significant evidence for linkage in the chromosomal region 19p12-q13 (LOD score 3.48). Mutation screening of positional candidate genes identified a synonymous SCN1B variant (c.492T>C, p.Tyr164Tyr) affecting splicing by the removal of a splicing silencer sequence, shown by in silico analysis, as the most likely causative mutation. In addition, the PRRT2 frameshift mutation (c.649dupC/p.Arg217Profs*8) was observed, showing incomplete, but high segregation with the phenotype. In vitro splicing assay of SCN1B expression confirmed the in silico findings showing a splicing imbalance between wild type and mutant exons. Herein, the involvement of the SCN1B gene in the etiology of BFIE, contributing to the disease phenotype as a modifier or part of an oligogenic predisposition, is shown for the first time.  Synonymous SCN1B variant most probably contributes to the BFIE phenotype as part of an oligogenic predisposition or as a modifier.
INTRODUCTION
Benign Infantile Seizures (BIS) is one of the three benign epilepsy syndromes others being BFIS (Benign Familial Neonatal Seizures) and BFNIS (Benign Familial Neonatal Infantile Seizures) that are characterized by partial seizures occurring in the first two years of life, however with different ages of onset. BIS was described by Fukuyama in 1963 as clusters of partial seizures with subacute onset between 3 to 20 months of age comprising motor arrest, impairment of consciousness, staring, and convulsive movements 1 . In 1992 Vigevano described the familial form of the disease and named it as
Benign Familial Infantile Convulsions/Seizures (BFIC or BFIS). The seizures are age dependent and patients have normal motor development before and after the disease duration 2 and is known to have an autosomal dominant mode of inheritance 3 . Herein, Benign Familial Infantile Epilepsy (BFIE) will be used instead of BFIS as suggested by the ILAE Commission on Classification and Terminology in 2010 4 .
Several linkage analyses in large families identified responsible loci in the chromosomal regions 19q12-13 5 , 16p12-q12 6 , 2q248 7 and 1p36.12-p35.1 8 , demonstrating genetic heterogeneity. However, it was lately shown that PRRT2 mutations were found in about 80% of BFIE families in various population 9, 10 . The PRRT2 (Proline Rich Transmembrane Protein 2) gene is located on chromosome 16 in a previously identified locus for BFIE and Paroxysmal Dyskinesia 11, 12 . Overall, 85 % of all reported PRRT mutations are truncating mutations occurring at the c.649
(c.649delC/p.Arg217Glufs*12 and c.649dupC/p.Arg217Profs*8), suggesting a mutation hotspot 13 . In their study Zara et al observed KCNQ2 mutations in all three phenotypes but PRRT2 mutations only in BFIE patients 14 .
Herein, we report a large multiplex family with a BFIE phenotype co-segregating with a synonymous variant in exon 4 of the SCN1B gene most probably affecting splicing efficiency of the mRNA, and with the known c.649dupC/p.Arg217Profs*8 mutation in the PRRT2 gene.
MATERIALS AND METHODS

DNA Samples
Patient recruitment and genetic analyses were conducted as recommended by the Boğaziçi University Ethical Committee and upon signed consent of the patients.
DNA was extracted from 10 ml peripheral blood of BFIE family members by the NaCI method 15 or from 2 ml peripheral blood by MagNa Pure DNA Isolation Kit-Large Volume on MagNA Pure penisilin/streptavidin, 1% N2 supplement, retinoic acid; final concentration 10 μM). Media was changed every 3 days and further differentiated for 9 days in culture. SH-SY5Y cells were transfected at the 5th day of differentiation according to manufecturer's protocol by using DNA: Lipo ratio of 0,2 μg DNA and 0,5 μl Lipofectamine 2000.
Two days after transfection total mRNA was isolated from differentiated SH-SY5Y cells using
Zymo quick RNA miniprep kit as described by the manufacturer. Reverse transcription PCR was conducted using the Qiagen Long-Range 2-Step RT-PCR kit. The target region was amplified by a LongRange PCR step using rat insulin exons specific primers. Primers for cDNA production; SCN1B mRNA F: CTCCCGGGGACATTCTAAC and SCN1B mRNA R: TTCAAGGCTGGTGAGAGAGG.
Targeted boost RT-PCR primers for all 3 transcripts were: SCN1B mRNA 2F:
CTATTAATACCGGCGGCCC and SCN1B mRNA 4&5 R: ATTACGGCTGGCTCTTCCTT. Rat insulin exon 3 and exon 2 specific primers: pSE-RNEx3-F GCCCTGCCCAGGCTTTTGTCA and pSE-RNEx2-R GCAGAGGGGTGGACAGGGTAG.
RESULTS
BFIE Family
The index patient (4BF14) was diagnosed with BFIE at age of 5 months, had typical symptoms of BFIE, namely seizures with deviation of head and eyes to one side, cyanosis, apnea and general motor arrest. Several members of the family had similar symptoms and seizure type during infancy and remission about a year later. All were responsive to phenobarbital and seizure free after 2-3 years of age without medication. Only one patient (4BF26) needed medication (carbamazepine) in order to be seizure free in adulthood (≥45 years old) ( Figure 4 ). 4BF17 deceased during the study. For other patients in generations III and IV clinical information were obtained during interviews with other family members especially with the member 4BF24. The pedigree was analyzed by Pedcheck 22 to confirm family relationships. The index patient was negative for mutations in the candidate genes SCN2A, and KCNQ2 by Sanger sequencing.
Genome-Wide Linkage Analysis
Whole genome multipoint linkage analysis with autosomal dominant inheritance and 70% penetrance identified a region with a significant LOD score of 3.48 on the chromosomal region 19p12-q13 ( Figure   1A ). Fine mapping defined the region of interest between markers rs959419 (chr19: 20826692, GRCh-37) and rs870379 (chr19: 35543756, GRCh-37) ( Figure 1B ). The haplotypes in the linkage region are shown in Figure 2 . The linkage region included the SCN1B gene together with 76 other protein-coding genes.
The plausible candidate SCN1B gene in the linkage region was sequenced revealing a synonymous SNP (rs535042320, NM_001037.3, c.492T>C; NP_001028.1, p.Tyr164Tyr) in exon 4 ( Figure 3A ).
The SNP is conserved in mammals, ultra-rare in the 282K samples of the Genome Aggregation it abolished a silencer sequence ( Figure 3B ).
Genome-wide Exome Sequencing
The patients 4BF14 and 4BF17 were analyzed by whole exome sequencing considering two facts: (i) that the SCN1B variant may be co-segregating with the disease due to the basic haplotype in the linkage region masking other mutations and (ii) that there was no other plausible candidate in the region.
Initially targeting the linkage region, filtering for unique variants shared by the two patients resulted in six variants in four genes, namely ZNF98, SCN1B, ZNF792, and GRAMD1A. Three other variants in two genes functionally similar to epilepsy related genes (SLC7A10 and KCTD15) were observed in one patient. All variations were validated by Sanger sequencing, except the variants in ZNF98 and SLC7A10. The variants in ZNF792, a gene with no expression in the brain, were in silico predicted to be benign. The GRAMD1A gene has minimal expression in the brain, as reported by the EMBL-EBI Expression Atlas 25 . On the other hand, the KCTD15 gene is known to be involved in the neural crest development 26 .
Genome-wide unique variants shared by two patients outside the linkage region were also analyzed.
When filtered for epilepsy and channel related genes that have expressions in the brain, 11 variants remained out of 6193 unique variants. While all 11 variants could be validated by Sanger sequencing, only two variants in EFHC1 and KCNJ10 were shared by other members of the family, but without a significant segregation with the phenotype or any evident modifying effect. However, a PRRT2 mutation (c.649dupC/p.Arg217Profs*8) 13 known to be the main cause for BFIE was observed in one patient. The mutation was confirmed by Sanger sequencing and analyzed in all family members. Out of 13 affected individuals 11 carried the mutation together with 6 unaffected individuals.
Supplementary Table 1 shows the two point LOD scores of all filtered variants based on the segregation analysis in the family. LOD scores were calculated using the SuperLink 17 program under the assumption of AD inheritance and 80% penetrance. The PRRT2 mutation has the lowest LOD score and the variants on 3 genes (SCN1B, ZNF792 and GRAMD1A) in the linkage region have the same LOD scores. KCTD15 gene variant which is also in linkage region has relatively high LOD score, however, wild type allele with global allele frequency of 0.62 was segregating together with the disease in the pedigree.
SCN1B cDNA Analysis
To see the effect of the silent mutation on splicing, total mRNA was isolated from the blood sample of the index patient (4BF14) and his parents (4BF15 and 4BF16) and was analyzed by two-step RT-PCR resulting in no alteration between affected and healthy individuals. These samples were also analyzed by Sanger sequencing that showed silent SCN1B c.492 T>C/p.Tyr164Tyr variation in heterozygous state in the patient indicating that there is expression from both alleles and eliminated the possibility of NMD of the mutant allele. Overall evaluation of RT-PCR results of mRNA isolated from blood show that silent mutation did not have any effect on splicing and expression of the gene.
In Vitro Splicing Assay (Minigene)
In order to see the effect of the mutation in nerve cells an in vitro splicing assay was conducted. The target exon was cloned into an expression vector through Gateway cloning system. In this expression vector target exon was surrounded with rat insulin exons used as a positive control of transfection and expression.
Validation of the Minigene Assay With A Known GABRG2 Splicing Mutation
Prior to testing the effect of SCN1B c.492T>C/p.Tyr164Tyr variation on splicing, the efficacy of the minigene assay was shown using a splice site variant on the GABRG2 gene (IVS6+2T>G). The mutation was reported by Kananura et al 27 and the splicing defect caused by the mutation was shown in both an in vitro system and also in a transgenic mouse by the retention of exon 6 into the intronic region 28 .
For the minigene assay GABRG2 mutation was created using site directed mutagenesis and cloned into 
DISCUSSION
In this study, genome-wide linkage analysis of a large multiplex BFIE family with an index patient negative for mutations in KCNQ2 and SCN2A genes resulted in a haplotype segregating with the disease with a significant LOD score of 3.48 in a 15 Mb region on the chromosomal segment 19p12-q13. This region has been previously reported as candidate linkage region for BFIE in five Italian families 5 . The mutational analysis of the most plausible positional candidate gene, the SCN1B gene, identified a synonymous nucleotide exchange (NM_001037.3 c.492T>C; NP_001028.1 p.Tyr164Tyr)
fully segregating with the disease phenotype.
In addition to the synonymous SCN1B variant, WES identified in the linkage region ZNF792, and GRAMD1A variants shared by both patients and co-segregating with the risk haplotype. ZNF792
is a zinc finger protein and may have a role in transcription regulation but not much is actually known about its function. According to the Expression Atlas database of EMBL-EBI 25 it is not expressed in brain and the effect of the variant was shown to be benign by in silico testing. The other segregating variant was a splice site variant in GRAMD1A that codes for GRAM domain-containing protein 1A, a seven pass transmembrane protein 29 . According to the Expression Atlas database of EMBL-EBI it has low expression in the brain and is a low frequency SNP in dbSNP (rs558298045). Both variants in SCN1B and GRAMD1A genes were not detected in at least 300 Turkish population controls. The frameshift mutation in KCTD15 gene was not shared by the two patients, but it was included in the segregation analysis due to its function in neural crest formation. However, the wild type allele showed incomplete segregation with the disease phenotype (LOD score of 2.02) leaving SCN1B as the most plausible candidate gene.
Genome-wide analysis of all other genes did not reveal any other causative variant shared by the two patients, but WES data of patient 4BF14 showed a known variant, c.649dupC/p.Arg217Profs*8, in the PRRT2 gene at 16q11.2, which is associated with the BFIE phenotype 10 . However, the variant was present in only 11 out of 13 affected individuals and also in 6 unaffected individuals. Reported penetrance of PRRT2 mutations is around 70%. Many reports of unaffected carriers of PRRT2 c.649dupC/p.Arg217Profs*8 mutation is attributed to diagnostic difficulties 13 , and that may also be the case in our family. However, affected individuals in this family were generally hospitalized due to long cluster of seizures and may not have escaped diagnosis.
Overall genome-wide linkage, WES and bioinformatic analysis emphasize the SCN1B synonymous c.492T>C/p.Tyr164Tyr variant and the PRRT2 649dupC frameshift mutation as the two strong candidates associated with the disease phenotype in the family.
The association of mutations in the voltage gated sodium channel beta 1 gene (SCN1B), which modulates channel surface expression and channel conduction properties, with epilepsy has been controversially discussed 30 . SCN1B gene resides on chromosome 19, in the frequently reported BFIE linkage region. There are reports of mutations in SCN1B for temporal lobe epilepsy (TLE), genetic epilepsy with febrile seizures plus (GEFS+) 31 and Dravet syndrome 32 . It is also reported that scn1b null mice have retarded growth, ataxia, spontaneous seizures and die in postnatal day 21 33 .The most striking feature of BFIE and the two other similar syndromes is their time dependent occurrence, which may be explained with temporal regulation of SCN1B splicing during mouse and human development. In human frontal lobe, the SCN1B isoform β1B (which is not a transmembrane protein and C terminus of the protein ends in intron 3 thus lacks exon 4) is expressed 10-fold higher than β1 variant at gestational week 22, and their levels become equal at week 36. However, after birth β1 level is 18-fold higher than β1B level 34, 35 . It might be speculated that tissue specific factors may be shifting the balance of splicing regulators so that β1 is expressed more than β1B.
The in-vitro effect of the SCN1B synonymous β1 variant (NM_001037.3, c.492T>C; NP_001028.1, p.Tyr164Tyr) was shown using the system developed by Kishore et al. 21 by constructing a splicing reporter assay with mutant and wild type SCN1B exon 4 and pSpliceExpress vector in neuroblastoma cells. The total mRNA produced by the reporter vector when amplified by two step RT-PCR shows proper splicing with both the wild type and variant exon 4, but inhibition of splicing of exon 4 in the variant seems to be removed resulting in an altered β1:β1B ratio. The large amounts of data generated by current technologies may actually have significant contributions to the understanding of basic genetic concepts such as low penetrance and modifier effects, however, the pedigree in Figure 4 showing the segregation of variants in SCN1B and PRRT2 genes do not give an obvious clue as to the modifier effects of variations in either gene. One homozygous affected member for the SCN1B variation did not have a more severe phenotype (4BF17).
The healthy phenotype of family members 4BF33 and 4BF85 (mother and son) who carry the variation in heterozygous and homozygous states respectively, have been confirmed by successive interviews with the family members. The observation of an unaffected individual homozygous for the SCN1B variant indicates an incomplete penetrance of the gene, in accordance with previous studies 38, 39, 40 .
The results presented suggest that the PRRT2 c.649dupC/p.Arg217Profs*8 frameshift mutation may not be sufficient to cause disease alone as it is present in several unaffected individuals. It may be concluded that the SCN1B c.492T>C/p.Tyr164Tyr splice site variant is also implicated in the etiology of BFIE in the family along with the known PRRT2 c.649dupC/p.Arg217Profs*8 frameshift mutation
and that both variants may be required to trigger disease, or that the SCN1B c.492T>C / p.Tyr164Tyr splice site variant acts as a modifier or as part of an oligogenic etiology. The role of the SCN1B variant in infantile epilepsy is not established and this report provides the first genetic evidence of SCN1B mutation causing the BFIE phenotype. Larger BFIE family cohorts should be investigated for SCN1B mutations and the synergistic effects of mutations in more than one gene. Contribution of SCN1B variants to BFIE phenotype may be underestimated when synonymous mutations may have been ignored in other BFIE families. Moreover, all of the reported pathologic SCN1B variants associated with other epilepsy syndromes were observed on the same gene region shared by the two splice variants β1 and β1B 41 .
